Startseite>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Proton Pump>>Caloxin 2A1 TFA

Caloxin 2A1 TFA

Katalog-Nr.GC62885

Caloxin 2A1 TFA ist ein Ca2+-ATPase (PMCA)-Peptidinhibitor der extrazellulÄren Plasmamembran.

Products are for research use only. Not for human use. We do not sell to patients.

Caloxin 2A1 TFA Chemische Struktur

Größe Preis Lagerbestand Menge
1 mg
45,00 $
Auf Lager
5 mg
99,00 $
Auf Lager
10 mg
162,00 $
Auf Lager
25 mg
324,00 $
Auf Lager
50 mg
486,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Caloxin 2A1 TFA is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg2+-ATPase or Na+-K+-ATPase[1].

Caloxin 2A1 TFA inhibits Ca2+-Mg2+-ATPase in human erythrocyte leaky ghosts, but it does not affect basal Mg2+-ATPase or Na+-K+-ATPase in the ghosts or Ca2+-Mg2+-ATPase in the skeletal muscle sarcoplasmic reticulum. Caloxin 2A1 TFA also inhibits Ca2+-dependent formation of the 140-kDa acid-stable acylphosphate[1].Caloxin 2A1 TFA increases airway smooth muscle cells (ASMCs) apoptosis[2].

[1]. J Chaudhary, et al. Caloxin: a novel plasma membrane Ca2+ pump inhibitor. Am J Physiol Cell Physiol. 2001 Apr;280(4):C1027-30.
[2]. Yi-fei Chen, et al. Plasma membrane Ca2+-ATPase regulates Ca2+ signaling and the proliferation of airway smooth muscle cells. Eur J Pharmacol. 2014 Oct 5;740:733-41.

Bewertungen

Review for Caloxin 2A1 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Caloxin 2A1 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.